- Home
- MEGL vs ASBP Comparison
MEGL vs ASBP Comparison
Compare MEGL & ASBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MEGL | ASBP |
|---|---|---|
| Founded | 2016 | 2021 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.8M | 6.8M |
| IPO Year | 2021 | 2021 |
Fundamental Metrics
Financial Performance| Metric | MEGL | ASBP |
|---|---|---|
| Price | $1.15 | $8.04 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 11.3K | ★ 26.6K |
| Earning Date | 04-10-2026 | 04-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.87 | $0.05 |
| 52 Week High | $1.90 | $8.18 |
Technical Indicators
Market Signals| Indicator | MEGL | ASBP |
|---|---|---|
| Relative Strength Index (RSI) | 46.39 | 61.10 |
| Support Level | $1.16 | $0.16 |
| Resistance Level | $1.39 | N/A |
| Average True Range (ATR) | 0.06 | 0.54 |
| MACD | -0.00 | 0.03 |
| Stochastic Oscillator | 20.83 | 96.38 |
Price Performance
Historical ComparisonAbout MEGL Magic Empire Global Limited
Magic Empire Global Ltd is a financial services provider in Hong Kong which principally engage in the provision of corporate finance advisory services and underwriting services. The company's offerings mainly comprise of IPO sponsorship services, Financial advisory and independent financial advisory services, Compliance advisory services, Underwriting services, Corporate service.
About ASBP Aspire Biopharma Holdings Inc.
Aspire Biopharma Holdings Inc is an early-stage biopharmaceutical company focused on developing and commercializing novel sublingual drug delivery technologies. The company is mainly engaged in advancing patent-pending formulations designed to enable rapid absorption of drugs, initially targeting high-dose aspirin products for cardiovascular and pain management applications. Its technology aims to improve efficacy and response time by bypassing the gastrointestinal tract through sublingual delivery.